DOI : 10.1055/s-00000054

Pharmacopsychiatry

Issue 02 · Volume 57 · March 2024 DOI: 10.1055/s-014-59266


XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP
Freiburg, Germany, 20.–22.03.2024

Organizing committee: Christian Fleischhaker, Hans-Willi Clement, Stefan Unterecker, Tom Utech, Eugenia Potapova
Program committee:
Stefan Unterecker / Chairman
Xenia Hart, Georgios Schoretsanitis,
Niels Bergemann, Hans-Willi Clement, Karin Egberts
Gerhard Gründer, Ursula Havemann-Reinecke, Gudrun Hefner,
Christoph Hiemke, Maike Scherf-Clavel
Abstracts (HTML) Abstracts (PDF) List of Authors
1
Gründer, G.: Positron emission tomography for optimizing psychiatric drug treatment: present and future
2
Paulus, W.: Antipsychotics in pregnancy – do we need Therapeutic Drug Monitoring?
3
Kittel-Schneider, S.: Update on the Management of Lithium in the Peripartum Period
4
Schoretsanitis, G.: Establishing therapeutic drug monitoring to routinely assess pharmacokinetic changes for psychotropic medications prescribed during pregnancy and lactation
5
Paulzen, M.: Psychotropic Medication and Breastfeeding – Yes – No – Maybe?
6
Hart, X. M.: Therapeutic Drug Monitoring of Antipsychotics: Innovations in the 2024 Consensus Guidelines
7
Toto, S.; Grohmann, R.; Bleich, S.; Seifert, J.: Drug safety in special populations: current data from the AMSP Project
8
Petri, H.: The influence of food on the pharmacokinetics of drugs
9
Müller, T.; Gerlach, M.; Hefner, G.; Jost, W.; Hiemke, C.; Riederer, P.: Therapeutic drug monitoring in Parkinson’s disease
10
Brauner, M.L.; Geffert, C.; Lukačin, R.; Clement, H.W.; Fleischhaker, C.: Clozapine Monitoring in Serum and Saliva
11
Egberts, K.; Fekete, S.; Taurines, R.; Gerlach, M.; Romanos, M.: Development of the first consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology for children and adolescents
12
Smigielski, L.; Tini, E.; Walitza, S.; Frey, M.; Egberts, K.: Therapeutic drug monitoring of children and adolescents treated with escitalopram in daily clinical practice
13
Liang, J.; de Winter, B.C. M.; Hermans, R. A.; Kloosterboer, S. M.; Bayraktar, I.; Hillegers, M.H. J.; van den Berg, S.A. A.; Koch, B.C. P.; Dierckx, B.: Risperidone plasma concentrations and side effects/effectiveness in children and adolescents with autism spectrum disorder
14
Molden, E.: Identifying CYP2C19 and CYP2D6 poor metabolizers from TDM data
15
Eap, C. B.; Ranjbar, S.; Gamma, F.; von Plessen, K. J.; von Gunten, A.; Conus, P.; Gras, C.; Piras, M.: CYP2D6 genotypes and phenotypes, plasma levels and treatment failure with risperidone or aripiprazole: results from a one-year longitudinal study
16
Demirbugen, Oz M.; Ozdemir, F.; Tok, K. C.; Dural, E.; Kir, Y.; Ulusoy, M.; Gumustas, M.; Baskak, B.; Suzen, H. S.: Assessment of Genetic and Lifestyle Factors on Clozapine and N-desmethylclozapine Plasma Levels in Schizophrenia Patients
17
Conca, A.; Marabese, A.; Paulmichl, M.; Giupponi, G.; Carpi, F.; Brigo, F.; Zaboli, A.; Mian, M.: Pharmacogenetics and TDM in patients with long-acting injectable antipsychotics: First clinical experience
18
Correll, C. U.: The value of therapeutic drug monitoring in the development of and treatment with long-acting injectable antipsychotics
19
Neumann, J.; Böttcher, M.: Therapeutic Drug Monitoring (TDM) in addiction medicine from the laboratory perspective
20
Zernig, G.: Degree of clinically quantified tolerance to the desired effects of and adverse drug reactions to the full mu opiod receptor agonist morphine, methadone and fentanyl and to the partial agonist buprenorphine during opioid maintenance and analgesic treatment
21
Pfeifer, P.: Therapeutic Drug Monitoring as part of the Opioid Withdrawal Therapy
22
Kuzin, M.: Therapeutic drug monitoring in the opioid substitution treatment
23
Müller, D. J.: Pharmacogenetics in Psychiatry: Precision medicine or ‘mystic, magic, and mysterious’?
24
Schwarz, M.: International Guidelines of pharmacogenetic testing focusing on pharmacokinetically relevant genes and there relevance in neuropsychopharmacology
25
Menke, A.: Pharmacogenetic testing for selection of antidepressant treatment
26
Weiner, R.M.: PGx and/or TDM? How could they interact in daily practice?